Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Sees Large Increase in Short Interest

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 33,566 shares, an increase of 2,234.2% from the December 15th total of 1,438 shares. Based on an average daily volume of 4,881 shares, the short-interest ratio is currently 6.9 days. Approximately 22.4% of the shares of the stock are sold short. Approximately 22.4% of the shares of the stock are sold short. Based on an average daily volume of 4,881 shares, the short-interest ratio is currently 6.9 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC grew its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 24,891 shares of the company’s stock after acquiring an additional 1,215 shares during the quarter. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Trading Up 0.3%

NYSEARCA THNR traded up $0.07 on Monday, hitting $26.18. 1,483 shares of the company’s stock were exchanged, compared to its average volume of 1,183. The stock has a 50-day moving average of $25.27 and a 200-day moving average of $23.92. The stock has a market cap of $3.93 million, a price-to-earnings ratio of 24.31 and a beta of 0.61. Amplify Weight Loss Drug & Treatment ETF has a 52 week low of $18.56 and a 52 week high of $26.44.

Amplify Weight Loss Drug & Treatment ETF Dividend Announcement

The firm also recently disclosed an annual dividend, which was paid on Wednesday, December 31st. Investors of record on Tuesday, December 30th were given a dividend of $0.4132 per share. This represents a dividend yield of 162.0%. The ex-dividend date was Tuesday, December 30th.

About Amplify Weight Loss Drug & Treatment ETF

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.